Guy Young

13.1k total citations · 4 hit papers
268 papers, 7.5k citations indexed

About

Guy Young is a scholar working on Hematology, Internal Medicine and Genetics. According to data from OpenAlex, Guy Young has authored 268 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 237 papers in Hematology, 61 papers in Internal Medicine and 43 papers in Genetics. Recurrent topics in Guy Young's work include Hemophilia Treatment and Research (171 papers), Blood Coagulation and Thrombosis Mechanisms (120 papers) and Platelet Disorders and Treatments (82 papers). Guy Young is often cited by papers focused on Hemophilia Treatment and Research (171 papers), Blood Coagulation and Thrombosis Mechanisms (120 papers) and Platelet Disorders and Treatments (82 papers). Guy Young collaborates with scholars based in United States, Italy and United Kingdom. Guy Young's co-authors include Diane J. Nugent, Johnny Mahlangu, Johannes Oldenburg, Flora Peyvandi, Elena Santagostino, Isabella Garagiola, Claude Négrier, Midori Shima, Christophe Schmitt and Rebecca Kruse‐Jarres and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

Guy Young

255 papers receiving 7.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2017 759 citations Johannes Oldenburg, Johnny Mahlangu et al. profile →
The past and future of haemophilia: diagnosis, treatments, and its complications

2016 321 citations Flora Peyvandi, Guy Young et al. profile →
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

2019 263 citations Guy Young, Tiffany Chang et al. Blood profile →
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

2023 67 citations Guy Young, Alok Srivastava et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Guy Young	6.2k	1.5k	987	798	791	268	7.5k
Roger E. G. Schutgens	2.9k 0.5×	988 0.7×	998 1.0×	701 0.9×	520 0.7×	229	4.7k
Diane J. Nugent	4.8k 0.8×	848 0.6×	665 0.7×	866 1.1×	505 0.6×	181	6.8k
Ri Liesner	5.2k 0.8×	1.6k 1.1×	323 0.3×	431 0.5×	531 0.7×	123	6.6k
Erik Berntorp	5.6k 0.9×	1.4k 1.0×	244 0.2×	600 0.8×	761 1.0×	164	6.3k
Erik Berntorp	5.5k 0.9×	1.4k 0.9×	309 0.3×	535 0.7×	653 0.8×	183	6.5k
P.M. Mannucci	3.1k 0.5×	643 0.4×	435 0.4×	709 0.9×	383 0.5×	129	4.7k
Paula Bolton‐Maggs	4.5k 0.7×	1.9k 1.3×	163 0.2×	660 0.8×	420 0.5×	158	6.7k
Luca Spiezia	1.3k 0.2×	258 0.2×	912 0.9×	444 0.6×	537 0.7×	146	3.4k
Pratima Chowdary	2.6k 0.4×	703 0.5×	166 0.2×	313 0.4×	498 0.6×	161	3.7k
Wolfgang Miesbach	1.7k 0.3×	371 0.3×	332 0.3×	314 0.4×	567 0.7×	192	3.2k

Countries citing papers authored by Guy Young

Since Specialization

Citations

This map shows the geographic impact of Guy Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Young more than expected).

Fields of papers citing papers by Guy Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Young. The network helps show where Guy Young may publish in the future.

Co-authorship network of co-authors of Guy Young

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Young. A scholar is included among the top collaborators of Guy Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Young. Guy Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Young, Guy, Kaan Kavaklı, Robert Klamroth, et al.. (2025). Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 145(25). 2966–2977. 7 indexed citations

Male, Christoph, Anthonie W.A. Lensing, Anthony K.C. Chan, et al.. (2025). Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. The Lancet Haematology. 12(5). e357–e364.

Abbas, Mohamed, Mehrdad Emami, Lauren Wilson, et al.. (2025). Pulsed-field ablation for atrial fibrillation in patients with cardiac implantable electronic devices. Heart Rhythm. 22(9). e594–e604. 1 indexed citations

Young, Guy, et al.. (2024). FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A. Blood. 144(Supplement 1). 2589–2589.

Kenet, Gili, Beatrice Nolan, Bülent Zülfikar, et al.. (2024). Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 143(22). 2256–2269. 16 indexed citations

Batsuli, Glaivy, Suchitra Acharya, Osman Khan, et al.. (2024). Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series. Haemophilia. 30(6). 1321–1331. 1 indexed citations

Jaffray, Julie, Brian R. Branchford, Neil A. Goldenberg, et al.. (2023). Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children’s Hospital Acquired Thrombosis consortium. Journal of Thrombosis and Haemostasis. 21(9). 2441–2450. 2 indexed citations

Young, Guy & Michael Makris. (2023). Time to revisit the classification of hemophilia: if it ain’t broke, don’t fix it!. Journal of Thrombosis and Haemostasis. 21(7). 1755–1756. 2 indexed citations

Meijer, Piet, Flora Peyvandi, Guy Young, et al.. (2023). International Council for Standardization in Haematology recommendations for laboratory measurement of factorVIIIandFIXtypeIinhibitors. International Journal of Laboratory Hematology. 45(4). 413–424. 10 indexed citations

10.

Nguyen, Anh, Julie Jaffray, Brian R. Branchford, et al.. (2022). Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital‐Acquired Thrombosis consortium. Research and Practice in Thrombosis and Haemostasis. 6(7). e12810–e12810. 4 indexed citations

11.

Tiede, Andreas, et al.. (2021). Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A. Haemophilia. 28(1). 27–35.

12.

Mancuso, Maria Elisa, Johnny Mahlangu, Robert F. Sidonio, et al.. (2020). Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study. Haemophilia. 26(6). 1009–1018. 18 indexed citations

13.

Konkle, Barbara A., Christopher Walsh, Miguel A. Escobar, et al.. (2020). BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 137(6). 763–774. 138 indexed citations

14.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations

15.

Jaffray, Julie, Brian R. Branchford, Neil A. Goldenberg, et al.. (2020). Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. The Journal of Pediatrics. 228. 252–259.e1. 25 indexed citations

16.

Young, Guy, et al.. (2020). FondaKIDS III: A long‐term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatric Blood & Cancer. 67(8). e28295–e28295. 2 indexed citations

17.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations

18.

Mancuso, Maria Elisa, Michael U. Callaghan, Rebecca Kruse‐Jarres, et al.. (2017). Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study. Blood. 130. 1071–1071. 14 indexed citations

19.

Santagostino, Elena, G. Auerswald, Víctor Jiménez‐Yuste, et al.. (2010). European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study. Haemophilia. 16(2). 407–407. 7 indexed citations

20.

Young, Guy, et al.. (2005). Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia. 11(3). 203–207. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact